Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Fighting post-COVID and ME/CFS - development of curative therapies

[img]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
421kB

Item Type:Article
Title:Fighting post-COVID and ME/CFS - development of curative therapies
Creators Name:Scheibenbogen, C. and Bellmann-Strobl, J.T. and Heindrich, C. and Wittke, K. and Stein, E. and Franke, C. and Prüss, H. and Preßler, H. and Machule, M.L. and Audebert, H. and Finke, C. and Zimmermann, H.G. and Sawitzki, B. and Meisel, C. and Toelle, M. and Krueger, A. and Aschenbrenner, A.C. and Schultze, J.L. and Beyer, M.D. and Ralser, M. and Mülleder, M. and Sander, L.E. and Konietschke, F. and Paul, F. and Stojanov, S. and Bruckert, L. and Hedderich, D.M. and Knolle, F. and Riemekasten, G. and Vehreschild, M.J.G.T. and Cornely, O.A. and Behrends, U. and Burock, S.
Abstract:The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No curative therapies are available for ME/CFS or PCS. The mechanisms identified so far provide targets for therapeutic interventions. To accelerate the development of therapies, we propose evaluating drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic and outcome criteria and subgrouping patients based on a thorough clinical profiling including a comprehensive diagnostic and biomarker phenotyping.
Keywords:COVID-19, Post-COVID, ME/CFS, Inflammation, Endothelial Dysfunction, Autoantibodies, Clinical Trials
Source:Frontiers in Medicine
ISSN:2296-858X
Publisher:Frontiers Media SA
Volume:10
Date:2023
Official Publication:https://doi.org/10.3389/fmed.2023.1194754
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library